Oxford Biomedica (OXB) Competitors GBX 412.50 0.00 (0.00%) (As of 12:24 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades OXB vs. ONT, GNS, ERGO, SLN, PRTC, HZD, VRP, BVXP, ARIX, and 4BBShould you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Oxford Nanopore Technologies (ONT), Genus (GNS), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Bioventix (BVXP), Arix Bioscience (ARIX), and 4basebio (4BB). These companies are all part of the "biotechnology" industry. Oxford Biomedica vs. Oxford Nanopore Technologies Genus Ergomed Silence Therapeutics PureTech Health Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Bioventix Arix Bioscience 4basebio Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations. Do analysts recommend ONT or OXB? Oxford Nanopore Technologies currently has a consensus price target of GBX 235.50, indicating a potential upside of 93.00%. Oxford Biomedica has a consensus price target of GBX 433.33, indicating a potential upside of 4.92%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oxford Nanopore Technologies 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Oxford Biomedica 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is ONT or OXB more profitable? Oxford Nanopore Technologies has a net margin of -94.82% compared to Oxford Biomedica's net margin of -145.98%. Oxford Nanopore Technologies' return on equity of -26.08% beat Oxford Biomedica's return on equity.Company Net Margins Return on Equity Return on Assets Oxford Nanopore Technologies-94.82% -26.08% -14.42% Oxford Biomedica -145.98%-124.66%-12.67% Does the media refer more to ONT or OXB? In the previous week, Oxford Nanopore Technologies and Oxford Nanopore Technologies both had 1 articles in the media. Oxford Nanopore Technologies' average media sentiment score of 1.21 beat Oxford Biomedica's score of 0.92 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oxford Nanopore Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oxford Biomedica 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ONT or OXB? Oxford Biomedica received 327 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 66.73% of users gave Oxford Biomedica an outperform vote. CompanyUnderperformOutperformOxford Nanopore TechnologiesOutperform Votes32100.00% Underperform VotesNo VotesOxford BiomedicaOutperform Votes35966.73% Underperform Votes17933.27% Do institutionals and insiders believe in ONT or OXB? 38.4% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 64.1% of Oxford Biomedica shares are owned by institutional investors. 32.6% of Oxford Nanopore Technologies shares are owned by insiders. Comparatively, 21.2% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, ONT or OXB? Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Oxford Biomedica, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOxford Nanopore Technologies£167.75M6.85-£159.06M-£0.20-610.10Oxford Biomedica£97.28M4.47-£142.02M-£1.44-286.81 Which has more risk & volatility, ONT or OXB? Oxford Nanopore Technologies has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Comparatively, Oxford Biomedica has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. SummaryOxford Nanopore Technologies beats Oxford Biomedica on 11 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Oxford Biomedica News Delivered to You Automatically Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OXB vs. The Competition Export to ExcelMetricOxford BiomedicaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£435.14M£164.86M£5.07B£1.39BDividend Yield4.57%3.25%4.99%11.73%P/E Ratio-286.81329.4787.861,549.36Price / Sales4.4714,996.691,228.82209,059.57Price / Cash3.0111.6739.5132.93Price / Book6.567.126.942.80Net Income-£142.02M-£18.52M£119.12M£152.70M7 Day Performance0.12%-0.22%-1.84%-0.51%1 Month Performance-0.48%8.10%-3.65%7.11%1 Year Performance115.10%26.08%31.64%91.82% Oxford Biomedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OXBOxford Biomedica0.9962 of 5 starsGBX 412.50flatGBX 433.33+5.1%+113.7%£434.61M£97.28M-286.46891Gap DownHigh Trading VolumeONTOxford Nanopore Technologies2.6671 of 5 starsGBX 122.80+0.3%GBX 235.50+91.8%-38.5%£1.16B£167.75M-612.001,281News CoveragePositive NewsHigh Trading VolumeGNSGenus2.1452 of 5 starsGBX 1,644-2.5%GBX 2,150+30.8%-24.0%£1.08B£668.80M14,050.00480ERGOErgomedN/AGBX 1,346flatN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AGBX 535-0.9%N/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech HealthN/AGBX 162+0.1%N/A-5.6%£387.86M£3.33M-702.61300HZDHorizon Discovery Group plc (HZD.L)N/AGBX 184.50flatN/AN/A£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AGBX 55+5.8%N/A+0.0%£228MN/A-1.6822Gap UpBVXPBioventixN/AGBX 3,710-1.1%N/A-5.2%£193.66M£13.60M2,298.1612ARIXArix BioscienceN/AGBX 142flatN/A+29.1%£183.73M£14.16M1,290.9194BB4basebioN/AGBX 1,310+0.8%N/A+146.8%£167.81M£311,000.00-1,666.67101Insider TradeNews Coverage Related Companies and Tools Related Companies Oxford Nanopore Technologies Alternatives Genus Alternatives Ergomed Alternatives Silence Therapeutics Alternatives PureTech Health Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Bioventix Alternatives Arix Bioscience Alternatives 4basebio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:OXB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.